BlueWhale Bio

About

BlueWhale Bio, Inc. is a biotechnology company focused on advancing cell and gene therapies by tackling key manufacturing challenges. Founded as a spinout from the University of Pennsylvania, the company aims to make these therapies more accessible, effective, and affordable for a wider patient population. The leadership team includes notable figures in immunotherapy, such as Carl June, MD, and James Riley, PhD, with Peter Keller serving as CEO. Headquartered in Philadelphia, BlueWhale Bio has raised $18 million in seed financing to support its mission. The company is developing a technology platform and product portfolio designed to enhance the efficacy and cost-effectiveness of cell therapies. Inspired by the role of whales in ecosystems, BlueWhale Bio seeks to innovate within the cell therapy landscape. The company is also actively hiring talent in science and business to drive its growth and commitment to innovation.